KPV Peptide: Research, Benefits & How It Works

KPV (Lys-Pro-Val) is a synthetic tripeptide that has been researched for decades for its potential role in modulating inflammatory signaling — particularly through the NF-κB pathway that drives pro-inflammatory cytokine production.

KPV corresponds to residues 11–13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid neuropeptide produced from the proopiomelanocortin (POMC) precursor. What makes KPV unusual is that it appears to retain much of the parent hormone’s anti-inflammatory activity while lacking the structural features responsible for alpha-MSH’s pigmentary and receptor-mediated effects — a distinction that has shaped the entire research program around it.

What Is KPV?

KPV is a chain of just three amino acids — lysine, proline, and valine (molecular weight ~342 Da) — matching the C-terminal sequence of alpha-MSH.

The story of KPV began in the 1980s in the laboratory of James Lipton at the University of Texas Southwestern Medical Center. Researchers studying alpha-MSH’s antipyretic (fever-reducing) properties systematically truncated the hormone to find the smallest fragment that kept working. They found that the COOH-terminal tripeptide carried a substantial share of the anti-inflammatory message: in rabbits, alpha-MSH(11-13) reduced fever, and in mice it inhibited chemically induced ear swelling in a dose-related fashion in experiments that used a large corticosteroid dose as a comparator.

A key structural point: alpha-MSH’s classic effects — pigmentation, appetite regulation, and signaling through the five melanocortin receptors (MC1R–MC5R) — depend on a central pharmacophore sequence (His-Phe-Arg-Trp) that KPV does not contain. As a later review put it, KPV “lacks the entire sequence motif required for binding to any of the known MC-Rs” yet “retains almost all of the anti-inflammatory capacity of the full hormone,” with no pigmentary action.

Research has investigated KPV for its potential effects on intestinal inflammation, NF-κB and MAPK signaling, macrophage and neutrophil behavior, antimicrobial activity, and cellular inflammatory responses in skin and neural tissue.

How Does KPV Work?

KPV has been studied for its interaction with inflammatory signaling at the cellular level. Researchers have investigated its relationship with:

• NF-κB inhibition — cell studies have reported that KPV and related alpha-MSH fragments suppress activation and nuclear translocation of nuclear factor kappa B, the transcription factor that drives expression of TNF-α, IL-6, IL-1β, and other pro-inflammatory cytokines
• MAPK signaling — intestinal research has examined KPV’s effects on mitogen-activated protein kinase inflammatory pathways alongside NF-κB
• The PepT1 transporter — studies have shown that KPV is taken up into intestinal epithelial cells via PepT1, an H⁺-coupled di/tripeptide transporter whose expression increases in inflamed colonic tissue, giving KPV a pathologically selective entry route
• Melanocortin-receptor independence — pharmacological and genetic studies have reported that KPV’s anti-inflammatory effects persist in mice with nonfunctional MC1R, are not blocked by the melanocortin antagonist SHU9119, and do not raise intracellular cAMP — distinguishing its mechanism from the parent hormone’s receptor-mediated signaling
• Cytokine modulation — animal and cell models have studied KPV’s association with reduced pro-inflammatory mediators including TNF-α, IL-1β, IL-6, IL-8, and interferon-γ
• Antimicrobial activity — laboratory work has investigated direct antimicrobial effects of KPV and alpha-MSH peptides against bacterial and fungal pathogens, proposed to act through cAMP-related mechanisms in the microbes themselves

Key Takeaway: KPV is particularly interesting to researchers because it appears to separate alpha-MSH’s anti-inflammatory activity from its receptor-mediated hormonal effects — working through a transporter-dependent, receptor-independent pathway that converges on NF-κB — though nearly all of this work remains preclinical.

Potential Benefits of KPV

Intestinal Inflammation Research

Intestinal inflammation is the most extensively studied area of KPV research.

In a widely cited 2008 study, researchers tested KPV in two mouse models of colitis — dextran sodium sulfate (DSS)-induced colitis and the CD45RB-high T-cell transfer model. They reported that KPV-treated animals showed earlier weight regain and improved histological findings, including reduced leukocytic infiltrate, submucosal edema, and crypt hyperplasia, compared to controls. Notably, the anti-inflammatory effects persisted in mice expressing a nonfunctional MC1R receptor, and in a severe DSS protocol, KPV treatment rescued all treated animals from death while all control animals died.

A separate 2008 study from a different laboratory investigated the uptake mechanism: when KPV was administered orally in the drinking water of mice with DSS colitis, the peptide was transported into intestinal cells via PepT1, and researchers reported inhibition of NF-κB and MAP kinase inflammatory signaling with reduced pro-inflammatory cytokine secretion.

The delivery science has continued: a 2017 study reported that KPV loaded into hyaluronic acid-functionalized nanoparticles, designed to target inflamed colonic tissue after oral administration, efficiently alleviated ulcerative colitis in a mouse model — reflecting ongoing research interest in getting the tripeptide to the site of intestinal inflammation.

Skin & Contact Hypersensitivity Research

KPV’s earliest in vivo findings were in skin inflammation models.

The 1989 study that launched KPV research reported dose-related inhibition of picryl chloride-induced ear swelling in mice. Follow-up work in 1990 extended these findings to acute inflammation and contact hypersensitivity more broadly.

Cell-level research has supported the skin connection: a 2004 study examined alpha-MSH, KPV, and related peptides’ signaling in human keratinocyte cells, the predominant cell type of the epidermis. A comprehensive 2008 review of alpha-MSH and related tripeptides surveyed their biochemistry and protective effects in vitro and in vivo, positioning the tripeptides as candidates for research into immune-mediated inflammatory conditions.

Acute Inflammation & Peritonitis Research

A 2003 pharmacological study directly compared KPV with the parent hormone and with core melanocortin peptides in a mouse model of urate crystal-induced peritonitis — the same type of crystal-driven inflammation involved in gout-like responses.

The study reported that systemic KPV treatment reduced leukocyte accumulation in the peritoneal cavity. Critically for the mechanism question, the researchers found that KPV’s effect was not blocked by the melanocortin antagonist SHU9119, did not raise cAMP in macrophages, and was retained in recessive yellow (e/e) mice with nonfunctional MC1R — while the parent hormone and receptor-targeted agonists behaved as classical melanocortin ligands throughout the same tests. The authors concluded the tripeptide was unlikely to act through those receptors.

Antimicrobial Research

A distinct line of research has investigated whether alpha-MSH peptides, including KPV, have direct antimicrobial properties.

A 2000 study reported that alpha-MSH and its C-terminal tripeptide KPV had antimicrobial effects against two representative pathogens: Staphylococcus aureus and Candida albicans. The peptides significantly inhibited S. aureus colony formation across a broad concentration range — including the physiological picomolar range — and reduced viability and germ-tube formation of the yeast C. albicans. The researchers proposed that the antimicrobial effect was mediated through increased cellular cAMP in the microbes, and noted that the peptides enhanced rather than reduced killing of pathogens by human neutrophils.

This dual profile — anti-inflammatory plus antimicrobial in laboratory models — has been noted as unusual, since conventional anti-inflammatory drugs typically impair rather than preserve host defense against microbes.

Cellular & Neuroinflammation Research

At the cellular level, a 1998 study reported that alpha-MSH completely abolished TNF-mediated NF-κB activation in a dose- and time-dependent manner, suppressing activation induced by multiple inflammatory stimuli (LPS, okadaic acid, ceramide) while leaving other transcription factors unaffected. A 1999 follow-up dissected the contributions of the core and C-terminal (KPV) sequences specifically.

In neural tissue, a 1999 study tested alpha-MSH(1-13) and alpha-MSH(11-13) — KPV — in cultured murine microglia stimulated with beta-amyloid protein and interferon-gamma. The researchers reported that both peptides significantly inhibited release of nitric oxide and TNF-α, and suppressed accumulation of inducible nitric oxide synthase (iNOS) mRNA — findings the authors framed as relevant to modulating local inflammatory responses in neurodegenerative contexts, all in cell culture.

It is important to distinguish these laboratory and animal findings from demonstrated outcomes in humans.

KPV vs. Other Peptides

KPV has a different research profile from peptides such as GHK-Cu, TB-500, and BPC-157, which are researched for different biological pathways.

GHK-Cu is a naturally occurring copper-binding peptide studied primarily for skin biology, collagen-related processes, and tissue remodeling.

TB-500 (a fragment of thymosin beta-4) has been studied in animal models for cell migration and tissue repair through actin regulation, with a research focus on wound healing and cellular movement.

BPC-157 is a synthetic 15-amino-acid peptide studied primarily in animal models for tendon, ligament, muscle, and gastrointestinal healing, with mechanisms investigated through FAK-paxillin and angiogenesis-related signaling.

KPV’s research is more closely associated with:

Inflammatory Signaling → NF-κB → Cytokine Modulation

What sets KPV apart is its origin story: it is a fragment defined by carrying the anti-inflammatory message of a hormone while leaving the hormone’s receptor pharmacology behind — making it the most inflammation-focused peptide in this group.

Regulatory Status

KPV’s regulatory position is worth stating plainly:

• KPV is not FDA approved for any indication, and no KPV drug product has been approved anywhere as a medicine.
• KPV was classified as an FDA 503A Category 2 bulk drug substance, meaning it was prohibited for use in compounding by licensed U.S. pharmacies.
• In April 2026, the FDA removed KPV from Category 2 — a procedural change, not an authorization to compound. KPV was subsequently scheduled for evaluation by the FDA’s Pharmacy Compounding Advisory Committee (PCAC) for possible inclusion on the 503A Bulks List. Like all PCAC proceedings, this is an advisory evaluation only: the FDA retains final authority, formal rulemaking is still required, and it does not constitute FDA approval. As of this writing, KPV remains not legal to compound.

Regulatory developments do not change the underlying evidence base: there are no human data.

What Does the Research Say?

The KPV literature provides a basis for continued research into transporter-dependent anti-inflammatory signaling, particularly in intestinal inflammation models and NF-κB pathway biology.

The mechanism work is unusually well replicated across independent laboratories — the Lipton/Catania group, the Luger group, the Merlin group, and the Getting/Perretti group have all reported convergent findings on KPV’s receptor-independent anti-inflammatory activity in animal and cell models. The colitis findings in particular have been reproduced with different models, different routes of administration, and different delivery technologies.

However, the gap between the preclinical literature and human evidence is complete: no human trial of KPV has been published, and no registered clinical trial of KPV exists. There is no established human safety profile and no human efficacy data of any kind. Much of the foundational NF-κB mechanism work was conducted with full-length alpha-MSH rather than the KPV fragment itself, and the exact intracellular signaling pathway KPV uses after PepT1-mediated entry is still being characterized.

Promising animal research is not the same as proven outcomes in people, and the enthusiasm around KPV runs well ahead of what the evidence supports.

Frequently Asked Questions

What is KPV?

KPV (Lys-Pro-Val) is a synthetic tripeptide corresponding to residues 11–13 of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been researched primarily in animal and cell models for its relationship with inflammatory signaling pathways, especially NF-κB.

Is KPV the same as alpha-MSH?

No. Alpha-MSH is the full 13-amino-acid hormone; KPV is a synthetic fragment containing only its last three residues. KPV lacks the central pharmacophore sequence the parent hormone uses to bind melanocortin receptors, and studies have reported that its anti-inflammatory effects persist without functional melanocortin receptor signaling.

What does the research show?

Animal and cell studies have reported reduced intestinal inflammation in multiple mouse colitis models, inhibition of NF-κB and MAPK signaling, reduced pro-inflammatory cytokine output, diminished leukocyte accumulation in crystal-induced peritonitis models, and direct antimicrobial effects against S. aureus and C. albicans in laboratory assays. All of this evidence is preclinical — there are no human data.

Is KPV FDA approved?

No. KPV is not FDA approved for any indication, and no KPV drug product has been approved anywhere. It was previously in FDA 503A Category 2 (prohibiting compounding), was removed procedurally in April 2026, and was scheduled for PCAC advisory evaluation — an advisory process only, not an approval.

Does KPV cause skin darkening or pigmentation?

In the published research, no. Alpha-MSH’s pigmentary effects come from its melanocortin receptor activity, which depends on a sequence KPV does not contain. A 2010 review specifically noted that KPV retains anti-inflammatory capacity while displaying “a lack of any pigmentary action.” This has been studied in laboratory and animal models only.

Has KPV been tested in humans?

No. The published KPV literature consists entirely of animal studies, cell-culture work, and reviews. No human clinical trial of KPV — controlled or otherwise — has been published, and no registered trial exists.

The Bottom Line

KPV is one of the most mechanistically interesting peptides in preclinical inflammation research — a three-amino-acid fragment that appears to carry the anti-inflammatory message of alpha-MSH through a transporter-dependent, receptor-independent pathway converging on NF-κB, with the deepest evidence in intestinal inflammation models.

The cross-laboratory consistency of the mechanism findings is genuinely unusual for a peptide this small — but it is still preclinical research. With zero human data published and no clinical trials registered, the evidence does not support conclusions about safety or effectiveness in people.

For researchers interested in inflammatory signaling biology, the KPV / alpha-MSH-fragment research area remains active and important — with the evidence belonging, for now, entirely to the laboratory.

Explore KPV

Learn more about KPV and explore our research-focused KPV peptide at Vonox Labs.

Research. Test. Learn.

Ver materiales de investigación: Tienda VONOX Labs

Research Use Only: Vonox Labs products are intended strictly for laboratory and research purposes and are not intended for human or veterinary consumption. This information is provided for educational purposes only and is not medical advice.

Scientific References

• Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-4. PMID 2550304. (Alpha-MSH[11-13] inhibited picryl chloride-induced ear swelling in mice in a dose-related fashion.)
• Hiltz ME, Lipton JM. Alpha-MSH peptides inhibit acute inflammation and contact hypersensitivity. Peptides. 1990;11:972-982.
• Manna SK, Aggarwal BB. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol. 1998;161(6):2873-80. PMID 9743348. (Full-length alpha-MSH; mechanistic context for the NF-κB pathway.)
• Galimberti D, et al. Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma. Biochem Biophys Res Commun. 1999. (Tested both alpha-MSH[1-13] and alpha-MSH[11-13] in cultured murine microglia.)
• Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239. PMID 10670585. (Alpha-MSH and KPV vs. Staphylococcus aureus and Candida albicans in laboratory assays.)
• Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306:631-637. (KPV in murine crystal-induced peritonitis; effect not blocked by SHU9119, no cAMP rise, retained in MC1R-deficient e/e mice.)
• Elliott RJ, et al. Alpha-melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004;122:1010-1019.
• Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346. (DSS and CD45RBhi transfer colitis models; effects persisted with nonfunctional MC1R.)
• Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177. (Oral KPV in DSS colitis; NF-κB and MAPK inhibition via the PepT1 transporter.)
• Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PMID 18612139. (Comprehensive review of alpha-MSH and related tripeptides.)
• Brzoska T, Luger TA. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010;681:107-116. PMID 21222263. (KPV lacks the MC-R binding motif yet retains anti-inflammatory capacity with no pigmentary action.)
• Xiao B, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. PMID 28143741.